Influence of spironolactone on neuroendocrine of SD rats with dilated cardiomyopathy
10.3724/SP.J.1008.2009.01022
- Author:
Jie BAI
1
Author Information
1. Department of Cardiology
- Publication Type:Journal Article
- Keywords:
Cardiomyopathy;
Neuroendocrine;
Spironolactone
- From:
Academic Journal of Second Military Medical University
2010;30(9):1022-1025
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study the effect of spironolactone, an aldosterone receptor antagonist (ARA), on neuroendocrine of SD rats with dilated cardiomyopathy, so as to investigate its mechanism in treatment of dilated cardiomyopathy. Methods: Male SD rats, weighting (300±50) g, were intraperitoneally injected with adriamycin (2 mg/kg) once a week for 8 weeks to induce dilated cardiomyopathy models. The rat models were randomly divided into 4 groups: control group, low dose spironolactone group (10 mg/[kg·d], i. g.], middle dose spironolactone group (20 mg/[kg·d], i. g.) and high dose spironolactone group (40 mg/[kg·d], i. g.). Rats in the normal control group received normal saline (10 mg/[kg·d], i. g.). Spironolactone was given for 8 weeks. Angiotensin II(Ang II) and aldosterone (ALD) levels in the plasma and cardiac muscle homogenate were determined 9 weeks later. The plasma nitrogen monoside (NO), N-terminal popeptide of collagen type III (P III NP) in serum and atrial natriuretic peptide (ANP) in the plasma were also measured. Results: Eight weeks after treatment, the Ang II levels in the plasma of animals in the middle dose group and high dose group were significantly decreased(P<0.05), the levels of ALD were elevated(P<0.05), those of P III NP and ANP were decreased(all P<0.05). Conclusion: Spironolactone at 20 mg/(kg·d) or 40 mg/(kg·d) for 8 weeks can correct the disorder in neuroendocrine system to some extents.
